Patients don't have to be perfect to manage their diabetes better.



"With my unpredictable schedule, injections fall short—I need a better way to stay consistent."

–Patient living with diabetes

GAPS IN MEETING ADA-RECOMMENDED GOALS

CDC NHANES data collected from 2009-2020 showed that only 25.2% of T1DM, 25.2% of T2DM (MTI), and 12.3% of T2DM (basal-only) achieved HbA1c targets.[1]

In a recent survey,

97% of diabetes patients said that they were **interested in pump therapy** if it could improve outcomes and is easy to learn and adopt.[2]

Could an insulin pump designed for easier adoption improve outcomes?

Pivot™ offers people who use daily insulin injections a more convenient way to manage insulin delivery—with confidence.

pivot™

Flip over to learn more, or visit
Pivotpump.com

Abbreviations: ADA, American Diabetes Assocations; CDC, Centers for Disease Control and Prevention; HbA1c, hemoglobin A1c; MTI, multiple treatment injections; NHANES, National Health and Nutrition Examination Survey; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

A pump built for patients who need multiple daily injections of insulin

Pivot™ provides steady, reliable basal insulin with the ease of push-button mealtime dosing—designed to fit your patient's life, not interrupt it.

pivot™



PUMP

- One-button functionality
- Tubeless design
- Innovative 3-piston diaphragm pump
- 90-day use
- Bluetooth and near field communication

CARTRIDGE

- 3-day use
- 3-mL or 300-unit reservoir
- Minimum fill of 30 units
- Disposable coin cell battery—no charging required
- Pump and cartridge can be suspended and removed from patch and then reapplied

PATCH

- 3-day use
- Applied via auto inserter
- Cannula is ~25-gauge diameter/6.6 mm length, made of linear low-density polyethylene

glooko® BETTER TOGETHER

The Glooko diabetes management platform simplifies diabetes care through seamless integration with Pivot™, enabling actionable insights to inform care.

Simplicity. Freedom. Thriving. That's Pivot™.

References: 1. Hankosky ER, Schapiro D, Gunn KB, Lubelczyk EB, Mitroi J, Nelson DR. Gaps remain for achieving HbA1c targets for people with type 1 or type 2 diabetes using insulin: results from NHANES 2009-2020. *Diabetes Ther*. 2023;14(6):967-975. doi:10.1007/s13300-023-01399-0
2. Data on File. Modular Medical 2026.

Learn more at Pivotpump.com

The Pivot™ Insulin Delivery System is indicated for the subcutaneous delivery of insulin at set and variable rates, for the management of diabetes mellitus in persons requiring insulin, for individuals 18 years of age and greater.

The Pivot™ Insulin Delivery System is contraindicated for use in diagnosing diabetes mellitus. It should not be used by patients who do not have adequate hearing and/or vision to recognize all system functions, including status indicators and alarms. Pivot™ is also contraindicated for patients who are unable to manage their diabetes therapy; who are unwilling to perform a minimum of four (4) blood glucose measurements per day; or who are unable or unwilling to use the system as described in the User Guide. Additionally, Pivot™ should not be used by patients who require basal insulin rates greater than 4 U/hr or less than 0.5 U/hr, or with insulin brands or concentrations other than Humalog® U-100 insulin or Lispro U-100 (Generic Humalog®).

© 2026 Modular Medical.

MKT-36 July 2026

Pivot and the Pivot logo are trademarks of Modular Medical. Glooko is a registered trademark of the Glooko Company. Humalog® is a registered trademark owned or licensed by Eli Lilly and Company.

pivot™ MODULAR MEDICAL